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Abstract A high priority in the prion field is to identify
pre-symptomatic events and associated profile of molecular
changes. In this study, we demonstrate the pre-symptomatic
dysregulation of cytoskeleton assembly and its associated
cofilin-1 pathway in strain and brain region-specific man-
ners in MM1 and VV2 subtype-specific Creutzfeldt-Jakob
disease at clinical and pre-clinical stage. At physiological
level, PrPC interaction with cofilin-1 and phosphorylated
form of cofilin (p-cofilin(Ser3)) was investigated in prima-
ry cultures of mouse cortex neurons (PCNs) of PrPC wild-
type and knockout mice (PrP−/−). Short-interfering RNA
downregulation of active form of cofilin-1 resulted in the
redistribution/downregulation of PrPC, increase of activat-
ed form of microglia, accumulation of dense form of F-
actin, and upregulation of p-cofilin(Ser3). This upregulated
p-cofilin(Ser3) showed redistribution of expression pre-
dominantly in the activated form of microglia in PCNs.
At pathological level, cofilin-1 expression was significant-
ly altered in cortex and cerebellum in both humans and
mice at pre-clinical stage and at early symptomatic clinical
stage of the disease. Further, to better understand the pos-
sible mechanism of dysregulation of cofilin-1, we also
demonstrated alterations in upstream regulators; LIM ki-
nase isoform 1 (LIMK1), slingshot phosphatase isoform 1
(SSH1), RhoA-associated kinase (Rock2), and amyloid
precursor protein (APP) in sporadic Creutzfeldt-Jakob dis-
ease MM1 mice and in human MM1 and VV2 frontal cor-
tex and cerebellum samples. In conclusion, our findings
demonstrated for the first time a key pre-clinical response
of cofilin-1 and the associated pathway in prion disease.
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uncover pre-clinical events and the alteration of associated pathway as
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stage, and the prion disease was diagnosed at a later date, this could be a
risk for public health and a concern to develop diagnostic tools by study-
ing early pre-clinical molecular pathways. To address this need, targeting
cofilin-1 activity in LIMK-APP-SSH1 signaling pathways might be a
promising strategy to study the most likely disease progression and the
internal homeostasis of misfolded proteins.
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Introduction
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common
form of prion diseases in humans [1]. Based on pathological
form of prion protein (PrPSc) electrophoretic mobility and alle-
lic variation at codon 129, sCJD has been divided into six
subtypes [2–4] among which sCJD MM1 and sCJD VV2 are
the two most commonly occurring subtypes [3]. Although
clinico-pathological features of the molecular disease subtypes
differ markedly by the affected brain area, severity, and mor-
phological features; but spongiform degeneration or severe
gliosis, neuronal loss, and dysfunction are critical and constant
features of CJD [5]. Synaptic loss and degeneration of the axon
terminal are early abnormalities in experimental scrapie [6, 7].
Indeed, accumulation of pathological form (PrPSc) of prion
triggers a pathological mechanism leading to synaptic abnor-
malities [5]. Recently, a role of PrPC in control of neurite
sprouting and dendritic spine formation has been described
through the modulation of actin dynamics [8, 9].
Actin cytoskeleton is crucial for neurite growth cone, spine
development, and formation of synapses in neurons [10–12].
Perfect balance in remodeling of actin is required for matura-
tion and maintenance of the synapses by regulating spine mor-
phology [13–17]. In mammals, the actin-depolymerizing factor
(ADF)/cofilin family of proteins, consisting of cofilin-1 (a non-
muscle type), cofilin-2 (a muscle-type), and ADF (also known
as destrin), is the major and critical regulator of actin dynamics
and reorganization by depolymerization and severing of actin
filaments [18–20]. A growing body of evidence provides sup-
port to a link between neurite transportation abnormalities and
synaptic plasticity impairment observed in neurodegenerative
diseases [21], as well as alterations in the organization and
dynamics of the actin cytoskeleton initiated by cofilin-1 [19,
22–25]. The regulatory response of cofilin-1 activity is quite
complex and is maintained by a cohort of kinases and phos-
phatases [26]. In particular, cofilin-1 is inactivated by LIM
kinase isoform 1 (LIMK1)-mediated phosphorylation at serine
3 (Ser3) that halts its actin binding activity, and dephosphory-
lation by slingshot phosphatase isoform 1 (SSH1), reactivates
cofilin-1 [19, 25, 27–29]. Although other kinases and phospha-
tases can also affect cofilin-1 activity, LIMK1 and SSH1 show
the highest substrate specificity [26]. Remarkably, phosphory-
lation of LIMK1 at threonine 505 and 508 activates it, and
phosphorylation at serine 937 and 978 inactivates SSH1 [30].
Further, not only cofilin-1 but also LIMK1 is dephosphorylat-
ed by SSH1 activity. So, SSH1 can control cofilin-1 activity
either directly or indirectly through an upstream regulation of
LIMK1 [30]. Moreover, SSH1 is also a potential interactor of
14-3-3 protein [31], and 14-3-3 is known to be markedly ele-
vated in the CSF of CJD patients [32–34].
In this study, our main objective was to uncover molecular
changes in cofilin-LIMK pathway, a major regulator of actin
dynamics, in two most frequent subtypes of sCJD (MM1 and
VV2) and in a mouse model at pre-symptomatic and symp-
tomatic stages of the disease. Interaction between PrPC and
cofilin-1, as well as its phosphorylated form, was investigated
in cellular model. This study demonstrated that regulation of
cofilin-LIMK pathway is altered in sCJD in a brain region-
and subtype-specific manner. Remarkably, dysregulation of
cofilin-LIMK pathway at pre-symptomatic stage of the dis-
ease signifies events initiated early in the pathological cas-
cade. Meanwhile, translation study in primary cultures of
mouse cortex neurons (PCNs) demonstrated the functional
aspect of cofilin-1 depletion on actin dynamics, microglial
activation, and upregulation/redistribution of phosphorylated
form of cofilin at clinical stage of the disease in humans.
Further differential manifestation/regulation of cofilin-LIMK
pathway in both subtypes of sCJD provides potential new
insights into the molecular mechanisms involved in pathology
and heterogeneity of prion diseases.
Materials and Methods
Ethics Statement
Human samples from the Institute of Neuropathology Brain
Bank (HUB-ICO-IDIBELL Biobank) and Biobank of
Hospital Clinic-IDIBAPS were obtained following the
Spanish legislation (Ley de la Investigación Biomédica 2013
and Real DecretoBiobancos 2014) and the approval of the
local ethics committees.
All animal experiments were performed in accordance with
the ethical standard set by Regierungspräsidium Tübingen
(Regional Council) Experimental No. FLI 231/07 file refer-
ence number 35/9185.81-2. All animal experiments have been
performed in compliance with the institutional and French
national guidelines, in accordance with the European
Community Council Directive 86/609/EEC. The experimen-
tal protocol was approved by the INRA Toulouse/ENVT
ethics committee.
CJD Patients, Samples Processing, and Subtype
Characterization
In this study, 30 pathologically confirmed sCJD patient’s brain
tissue samples, i.e., frontal cortex and cerebellum regions (15
of eachMM1 and VV2 subtypes) and 15 age-matched control
cases (CON) were analyzed. All 45 samples were obtained
from the Institute of Neuropathology Brain Bank (HUB-
ICO-IDIBELL Biobank) and Biobank of Hospital Clinic-
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IDIBAPS. The mean age and gender of study cases were as
described previously [35, 36]. In brief, for sCJD frontal cortex,
60 years of mean age in control (10M/5F), 68 years of mean
age in sCJD MM1 (10M/5F), and 63 years of mean age in
Fig. 1 Interactive association between PrPC and cofilin-1. Primary
cultures of mouse cortex neurons (PCNs) encoding PrP gene and
knockout (PrP−/−) were prepared from pregnant mice at embryonic day
14. a Total cellular lysate co-immunoprecipitated (IP) with PrPC antibody
(lane 1 PrP−/− PCNs and lane 2 PrPC-expressing PCNs); cofilin-1
antibody (lane 3 PrP−/− PCNs and lane 4 PrPC-expressing PCNs); and
then immunoblotted with SAF70 PrPC, cofilin-1, and p-cofilin(Ser3)
antibodies. b, c Western blot with PrPC and cofilin-1 from fractions
isolated after ultracentrifugation using sucrose step gradient.
Densitometry analysis from four independent (±SD) sedimentation
ultracentrifugation fractionation experiments. d PrPC and cofilin-1
distribution was analyzed in primary cultures of mouse cerebellar granule
neurons (PCGNs) and primary mouse corticle neurons (PCNs) using 3F4
anti-PrPC (red), anti-cofilin-1 (green) antibodies, and DAPI (blue-nuclear
staining). At least 35 cells were observed per condition per experiment for
an equal exposure time (Scale bar 10 μm). The co-localization scatter
frequency plots of the individual pixels from paired images and
co-localization frequency graphs were generated by ImageJ (WCIF
plugin) software. e, f Pearson’s colocalization correlation coefficient rp
(−1 ≤ rp ≤ 1) showed % co-localization and % correlation btween PrPC
and cofilin-1 in cerebellar granule neuron and in cortical neurons. Graph
was generated by ImageJ (WCIF plugin) software
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sCJD VV2 (5 M/10F). In cerebellum, the mean age was
62 years in control (11M/4F), 66 years of mean age in sCJD
MM1 (10M/5F), and 63 years of mean age in sCJDVV2 (4M/
10F). After post-mortem interval ranging 1 h 45 min to 24 h
30 min, coronal sections 1 cm thick were cut from one of the
hemispheres. Along with selectively dissected areas of en-
cephalon, coronal sections were rapidly frozen onmetal plates
over dry ice, sorted in separate bags, labeled with water-
resistant ink and stored at −80 °C until further use for bio-
chemical investigations. The other hemisphere was fixed in
4% buffered formalin for 3 weeks for morphological studies
and neuropathological examination and characterization. The
analysis of the codon 129 genotype of PrP gene (Met: M or
Val: V) was performed after isolation of genomic DNA from
blood samples according to standard methods. Western blot
profile of PrPSc was classified as type 1 or type 2 based on
electrophoretic mobility after proteinase K (PK) digestion.
sCJD MM1 and VV2 Transgenic Mice
Double transgenic Tg340 mice overexpressing about 4-fold
level of human PrPC with methionine at codon 129 (Met129
and Val129) on a murine PrP knockout background were
used, as described previously [9, 36, 37]. Inocula were pre-
pared from sCJD MM1 and VV2 brain tissues as 10% (w/v)
homogenates. Individually identified 6- to 10-week-old mice
were anesthetized and inoculated with 2 mg of brain
homogenate in the right parietal lobe using a 25-gauge dispos-
able hypodermic needle (six animals per group and time
point). Mice were observed daily, and the neurological status
was assessed weekly. When disease progression was evident,
or at the end of lifespan, animals were euthanized, necropsy
was performed, and the brain was removed. A part of the brain
was fixed by immersion in 10% buffered formalin to quantify
spongiform degeneration and perform immunohistological
procedures. The other part was frozen at −80 °C to extract
protein. Survival time was calculated for each isolate and
expressed as the mean of the survival day post-inoculation
(dpi) of all mice scoring positive for PrPSc. Infection rate
was determined as the proportion of mice scoring positive
for PrPSc from all inoculated mice.
Primary Culture of Mouse Cortex, Cerebellum, Gene
Manipulation, Transfection, and RNAi
PCNs and cerebellum (PCE) were prepared as described pre-
viously [36, 38]. In brief, embryos were removed from preg-
nant mice at embryonic day 14 under halothane (Sigma) an-
esthesia; the mice were prnp (the PrP-encoding gene) and
knockout (PrP−/−) [39]. Animals were killed by cervical dis-
location and the dissected embryonic cortex was mechanically
dissociated and plated on polyethylenimine (1 mg/ml)-coated
glass coverslips in culture wells.
Fig. 2 Cofilin-1, p-cofilin(Ser3), LIMK1, and P-LIMK1 expressions in
sCJD MM1 and VV2 subtypes. Western blotting analysis: a cofilin-1, p-
cofilin(Ser3), LIMK1, and P-LIMK1 in four representative cases each for
control, sCJD MM1, and sCJD VV2 cases; GAPDH immunostaining
was used to normalize total protein loading. b, c Densitometry analysis
from four independent (±SD) immunoblotting experiments of 15 control
(Con), 15MM1, and 15 VV2 cases. The significance was calculated with
one-way ANOVA Friedman test (*P < 0.05, **P < 0.01, ***P < 0.001).
AU arbitrary units
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After 3 days in vitro (DIV), the medium was replaced with
N5 medium [40] with 180 mg/L glucose and supplemented
with 5% FBS and 1% FCS. Three micromolars of cytosine
arabinoside was added to prevent astrocyte proliferation
(resulting in at least 97% pure neuronal cultures) and 1 μM
MK-801 to prevent excitotoxicity [41]. The medium was
changed daily. On DIV 5, FCS was removed and the FBS
content was reduced to 1%.
The cells were seeded in complete DMEM prior to tran-
sient transfection with plasmid and short-interfering RNA
(siRNA) duplexes using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. Cofilin-1 siRNA duplex had a sense strand 5′-GGAG
GACCUGGUGUUCAUC-3′ [42], and non-targeting siRNA
duplex (control siRNA duplex negative control: Eurogentec)
[9] was used as a negative control.
Assessment of Neuronal/Cell Viability and Caspase-3
Activity Assay
The viability of neurons in primary cortical cultures, with and
without depletion of cofilin-1 and in the presence of PrPC, was
checked by counting number of healthy nuclei per unit area
after Hoechst staining. The identification of individual neuron
viability that was unequivocally healthy on the basis of its
nuclear appearance using a combination of fluorescent illumi-
nation and phase contrast [43].
Cell viability assay was performed as described previously
[44]. Briefly, the adherent cells were grown up to 60–70%
confluency and then detached from flasks using 1× Trypsin-
EDTA. The cells were spun down at 4 °C for 5 min at 400×g
and resuspended in culture media. Cells were then dispensed
into 24-well plates (Nunc, Roskilde, Denmark) at a final con-
centration of 1 × 105 cells/well and incubated for 12 h. The
culture media were then removed and replaced prior to MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl) 2H-tetrazolium, inner salt] treatment. The
effect of the presence of PrPC and the treatment of TNF-
alpha on cell viability was measured using the MTS cell pro-
liferation assay, which measures the reduction of MTS tetra-
zolium salt to formazan in metabolically active cells [45]. The
cells were then treated with 1:20 ratio of MTS reagent
(Promega Co. Madison, WI, USA) 2 mg/ml with 0.5% glu-
cose and PMS 0.92 mg/ml with 0.5% glucose. Cells were
incubated for 1 h at 37 °C for color development, and the
absorbance values were read at 490 nm using a Multiscan
Plate Reader (Labsystems, VA, USA) and Accent software
2.6. Background absorbance from controls was incubated in
media with the MTS reagent and was subtracted from sample
wells after the final absorbance was obtained.
The caspase-3-activity assay allows quantitative measure-
ment of caspase-3 (DEVDase) protease activity, which is an
early regulatory event in the apoptotic cell death process. The
assay was performed using caspase-3 activity assay kit accord-
ing to the manufacturer’s recommendations. Briefly, cofilin-1
depleted PCNs were lysed in the cell lysis buffer for 15 min at
4 °C, and this was followed by centrifugation at 10,000×g.
Protein concentration was estimated from the supernatants,
and the total cell lysate (50 μg) was then incubated with
50 μM caspase-caspase-3-specific substrate DEVD-pNA
(Asp-Glu-Val-Asp p-nitroanilide) for 4-5 h at 37 °C. The
caspase-3 inhibitor Z-vad-FMK (20 μM) was used as control.
Caspase-3-mediated release of pNA was measured by absor-
bance at 405 nm. Background absorbance from the control
(untreated cells) was subtracted from the samples after the final
absorbance was obtained.
Co-sedimentation Assay
Two hundred microliters of 10% brain homogenate in PBS
containing 2% w/v sarkosyl (pH 7.4) were clarified for 5 min
at 500×g, and were carefully layered onto the top of 10–60%
sucrose step gradient. Gradients were prepared in thin wall
polyallomer tubes (11 × 34mm, 2.2 ml, Beckman), and sucrose
serial dilutions (10, 12.5, 15, 17.5, 20, 22.5, and 60%,w/v) were
made in PBS containing 1% sarkosyl (pH 7.4). All the gradients
in an experiment were prepared with a same batch of buffers.
For avoiding mixing of sucrose serial dilutions while setting
gradient in tubes, tubes (sucrose layers) were frozen for
10min at −80 °C after adding each sucrose layer; and next layer
was then added over previous frozen layer. Ultracentrifugation
was performed at 55,000 rpm for 5 h at 5 °C in Optima™ TL
Ultracentrifuge (Beckman Coulter) equipped with Beckman
Coulter TLS-55 rotor. These conditions corresponded to
RCF = 259,000×g, angular velocity ω = 5759.59 rad/s, and k
factor = 50. After centrifugation, 20 fractions, 100μl each, were
collected carefully from top to bottom in separate tubes and
proceeded for immunoblotting.
Co-immunoprecipitation
Cell lysis was performed as described previously [9, 46], and
the insoluble cell debris was removed by centrifugation at
543,000×g for 15 min at 4 °C. Immunoprecipitation was per-
formed using magnetic Dynabeads protein G, according to the
manufacturer’s instructions. Total cytoplasmic cell extracts or
immunoprecipitated proteins (corresponding to 2 × 106 cells/
lane) were subjected to 12.5% 1-DE SDS-PAGE and, after
transferring to polyvinylidenedifluoride membranes
(Millipore), immunoblotting was performed as described
above.
Co-immunofluorescence Confocal Microscopy
PCNswere platted on chambered slides [Lab-Tek™ II; Thermo
Fisher Scientific (Nunc GmbH & Co. KG), Langenselbold
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Site] and lipotransfected with cofilin-1 siRNA. Subsequently,
they were washed in 1× PBS and then fixed for 15 min with
100% ethanol. After fixation, cells were permeabilized with
0.2% Triton X-100 in 1× PBS, followed by a 20-min blocking
step using 0.2% casein-solution containing Tween 20. Co-
localization of F-actin with cofilin-1, PrPC with Iba1 and p-
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cofilin(Ser3), and cofilin-1 with p-cofilin(Ser3) was detected by
exposure to the primary antibodies [anti-PrP 3F4
(1:200), mouse anti-cofilin-1 (1:100), mouse anti-F-
actin (1:100), mouse anti- p-cofilin(Ser3) (1:100)] over-
night at 4 °C. The monoclonal antibodies were detected
by incubating slides for 60 min with Alexa 488 conju-
gated anti-rabbit (1:200), Alexa 488 conjugated anti-
mouse (1:200), or Cy3-labeled anti-mouse secondary an-
tibody (1:200). Incubation with TO-PRO-3 iodide for
10 min was performed to visualize nuclei. Finally, cov-
erslips were placed on the glass slides which were then
mounted with Fluoromount (DAKO, Hamburg,
Germany). All the steps were further carried out as de-
scribed previously [9].
Antibodies, Reagents, and Immunoblot Analysis
Mouse anti-PrP mAb SAF32, mouse anti-PrP mAb SAF70
(1:1000; SpiBio, Paris, France), mouse anti-PrP 3F4 mAb
(1:1000; Merck Millipore, Darmstadt, Germany), rabbit anti-
cofilin mAb (1:1000; Sigma-Aldrich, Munich, Germany),
rabbit anti-cofilin (phospho S3) mAb (1:500), mouse anti-
GAPDH mAb (1:1000), mouse anti-LIM kinase 1 mAb
(1:500), rabbit anti-LIM kinase 1 (phospho T508) pAb
(1:500), rabbit anti-slingshot homolog 1L pAb (1:1000), rab-
bit anti- RhoA-associated kinase (Rock2) pAb (1:500), rabbit
anti-Iba1 mAb (1:1000), mouse anti-amyloid beta A4 protein
mAb (1:1000), and rabbit anti-calcineurin A mAb (1;1000)
from Abcam, Cambridge, UK were used as primary antibod-
ies. HRP-conjugated rabbit anti-mouse pAb (IBA,
Goettingen, Germany), HRP-conjugated goat anti-rabbit
pAb (Jackson ImmunoResearch Laboratories Europe, Ltd.),
goat anti-mouse pAb cy3-conjugated (Dianova, Hamburg,
Germany), anti-rabbit pAb (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), goat anti-rabbit (Alexa 488-conjugat-
ed), and anti-mouse (Alexa 488-conjugated) were used as sec-
ondary antibodies. Protease and phosphatase inhibitor cocktail
(Roche, Mannheim, Germany), Hoechst 33342 (Sigma-
Aldrich, Steinheim, Germany), halothane anesthesia, cytosine
arabinoside (Sigma, St. Louis, MO, USA), MK-801
(Research Biochemicals International), penicillin, and strepto-
mycin (Gibco) were also used.
Cell lysis and immunoblotting were performed as de-
scribed previously [36, 46]. Briefly, cells were lysed
(50 mM Tris-HCl, pH 8, 1% Triton X-100, 0.5% CHAPS,
1 mM DTT), and lysates were cleared of cell debris (1 min,
1000×g, 4 °C). Cell lysates were supplemented with protease
and phosphatase inhibitors (Roche) and were separated on
12.5% 1-DE SDS-PAGE. Expression of proteins was ana-
lyzed by immunoblot using overnight exposure at 4 °C to
anti-PrP SAF70 mAb (1:1000), anti-cofilin mAb (1:1000),
anti-cofilin (Phospho S3) mAb (1:1000), anti-GAPDH mAb
(1:1000), anti-LIM Kinase 1 mAb (1:500), anti-LIM kinase 1
(Phospho T508) pAb (1:500), anti-slingshot homolog 1L pAb
(1:1000), anti-Rock2 pAb (1:500), rabbit anti-Iba1 mAb
(1:1000), anti-amyloid beta A4 protein mAb (1:1000), and
anti-calcineurin mAb (1;1000). Membranes were then rinsed
in 1× TBS-T and incubated with the corresponding horserad-
ish peroxidase-conjugated secondary antibody (diluted
1:2000/1:5000) for 1 h at RT. Immunoreactivity was detected
after immersion of the membranes into enhanced chemilumi-
nescence (ECL) solution and exposure to ECL-Hyperfilm
(Amersham Biosciences, Buckinghamshire, UK). Images
were documented using the ScanMaker4 (Microtek,
International), after correction for the background, and band
intensities were determined by densitometry using Lab image
(version 2.7.1, Kapelan GmbH, Germany) data analyzer
software.
Statistical Analysis
All results in this study were obtained from at least four inde-
pendent sets of experiments and were expressed as
mean ± S.D. using descriptive statistics. Densitometric analy-
sis of 1-DE gels was performed using Labimage (version 2.7.1
Kapelan, Leipzig, Germany) software.
Results
Selective Interactive Association Between PrPC
and Cofilin-1
Previous studies have shown an interaction between PrPC/
PrPSc and cofilin-1, but the role of cofilin-1 in the pathogen-
esis of Prion diseases is still not clear [46, 47]. So firstly, we
were interested to explore interactive association between
PrPC and cofilin-1. For this, we co-immunoprecipitated
cofilin-1 from PrPC wild-type and PrPC knockout (PrP−/−)
primary cortical neurons (PCNs) using PrPC antibody by
Dynabeads G protein-coupled magnetic beads, and purified
eluates were co-immunoblotted with SAF 70 PrPC antibody
(Fig. 1a). No signal was detected using purified eluates from
Fig. 3 Expression of cofilin-1 and p-cofilin(Ser3) at pre-symptomatic
and symptomatic stage of sCJD MM1 and VV2 in mice. Tg340 mice
expressing about 4-fold level of human PrPM129 were infected with
sCJD MM1 and also VV2 10% brain homogenates. Samples were
collected at indicated days post-infection (dpi): pre-symptomatic stage
(60 dpi in VV2, 120 dpi in MM1) and symptomatic stages (120–
183 dpi in VV2 and 160–210 dpi). a, d Cofilin and p-cofilin(Ser3)
expression in the cortex and cerebellum were observed by Western blot
analysis using cofilin and p-cofilin(Ser3) antibodies. b, c, e, f
Densitometry analysis from four independent (±SD) immunoblotting
experiments of cofilin and p-cofilin(Ser3) from control and sCJD
MM1- and VV2-infected PrPM129 mice in cortex and cerebellum. The
significance was calculated with one-way ANOVA Friedman test
(*P < 0.05)
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PrP−/− PCNs (Fig. 1a, b). In order to further confirm these
observations, we co-immunoprecipitated PrPC using cofilin-
1 and p-cofilin antibodies (Fig. 1a). Eluates from this reverse
co-immunoprecipitation were immunoblotted again with
SAF70 PrPC antibody to verify the PrPC interaction (Fig. 1a,
b). Further, PrPC-expressing primary cortical cultures were co-
immunoprecipitated with PrPC and cofilin-1 antibodies
followed by immunoblotting with anti-cofilin-1 antibody to
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confirm the interaction (Fig. 1c). Likewise, confocal laser co-
immunofluorescence scanning showed region-specific co-lo-
calization of PrPC and cofilin-1 in PCNs and in cerebellar
neurons (PCB) (Fig. 1d–f). The Pearson’s correlation coeffi-
cient data demonstrated significant less co-localization of
PrPC with cofilin-1 in cortical neurons as compared to cere-
bellar granule neurons (Fig. 1e). However, correlation channel
did not show significant altered response (Fig. 1f). The inter-
active association between PrPC and cofilin-1 was further ver-
ified with co-sedimentation assay at steady state and striking-
ly, PrPC and cofilin-1 shared identical fractions and demon-
strated the selective functional association between cofilin-1
and PrPC (Fig. 1g, h).
LIMK1 Pathway Mediated Alteration of Cofilin-1
Expression/Activity in CJD MM1 and VV2 Patients
and in Pre-symptomatic and Symptomatic Stages of sCJD
MM1 and VV2 Mice
This interaction of cofilin-1 with PrPC suggests that there
might be some functional correlation. So accordingly, we
sought to explore molecular changes in cofilin-LIMK path-
way in cerebellum and frontal cortex of two most frequent
subtypes (MM1 and VV2) of sCJD, as well as age-matched
controls (15 samples in each group). Total homogenates of
the frontal cortex and cerebellum were analyzed using
Fig. 4 Expression of LIMK1 and P-LIMK1 at pre-symptomatic and
symptomatic stage of sCJD MM1 and VV2 in mice. Tg340 mice
expressing about 4-fold level of human PrPM129 were infected with
sCJD MM1 and also VV2 10% brain homogenates. Samples were
collected at indicated days post-infection (dpi): pre-symptomatic stage
(60 dpi in VV2, 120 dpi in MM1) and symptomatic stages (120–
183 dpi in VV2 and 160–210 dpi). a LIMK1 and P-LIMK1 expression
in the cortex and cerebellum of sCJD MM1 and VV2 in mice were
observed by Western blot analysis using LIMK1 and P-LIMK1
antibodies. d Dot blot analysis of P-LIMK1 in the cortex and cerebellum
were observed by Western blot analysis using LIMK1 and
P-LIMK1 antibodies. Frontal cortex (lane a1 = control 120 dpi, a2-
= control 160 dpi, a3 = control 183 dpi, a4 = control 210 dpi,
b1 = sCJD MM1-infected 120 dpi, b2 = sCJD MM1-infected 160 dpi,
b3 = sCJD MM1-infected 183 dpi, b4 = sCJD MM1-infected 210 dpi).
Cerebellum (lane a5 = control 120 dpi, a6 = control 160 dpi, a7 = control
183 dpi, a8 = control 210 dpi; b5 = sCJD MM1-infected 120 dpi,
b6 = sCJD MM1-infected 160 dpi, b7 = sCJD MM1-infected 183 dpi,
b8 = sCJD MM1-infected 210 dpi). b, c, e, f Densitometry analysis from
four independent (±SD) immunoblotting experiments of LIMK1 and P-
LIMK1 from control and sCJDMM1- and VV2-infected PrPM129 mice
in cortex and cerebellum. The significance was calculated with one-way
ANOVA Friedman test (*P < 0.05)
Fig. 5 Rock2 and APP in sCJD MM1 and VV2 subtypes. Western
blotting analysis: a Rock2 and APP in four representative cases each
for control , sCJD MM1, and sCJD VV2 cases ; GAPDH
immunostaining was used to normalize total protein loading. b
Densitometry analysis from four independent (±SD) immunoblotting
experiments of 15 control (Con), 15 MM1, and 15 VV2 cases. The
significance was calculated with one-way ANOVA Friedman test
(*P < 0.05, **P < 0.01, ***P < 0.001). AU arbitrary units
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cofilin-1 and p-cofilin(Ser3) monoclonal antibodies
(Fig. 2). Densitometry analysis revealed significantly al-
tered cofilin-1 expression at the protein level in the frontal
cortex in the sCJD MM1 subtype (Fig. 2c) and in the cere-
bellum of VV2 subtype as compared to age-matched control
subjects (Fig. 2a, c), showing that the response was region-
Fig. 6 Expression of Rock2 and APP at pre-symptomatic and
symptomatic stage of sCJD MM1 and VV2 in mice. Tg340 mice
expressing about 4-fold level of human PrPM129 were infected with
sCJD MM1 and also VV2 10% brain homogenates. Samples were
collected at indicated days post-infection (dpi): pre-symptomatic stage
(60 dpi in VV2, 120 dpi in MM1) and symptomatic stages (120–
183 dpi in VV2 and 160–210 dpi). a Rock2 and APP expressions in
the cortex and cerebellum were observed by Western blot analysis using
Rock2 and APP antibodies. b–e Densitometry analysis from four
independent (±SD) immunoblotting experiments of Rock2 and APP
from control and sCJD MM1- and VV2-infected PrPM129 mice in
cortex and cerebellum. The significance was calculated with one-way
ANOVA Friedman test (*P < 0.05, **P < 0.01, ***P < 0.001)
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and codon 129 polymorphism-specific. Interestingly, for
the phosphorylated form of cofilin-1, there was significant
upregulation in levels of p-cofilin(Ser3) in frontal cortex
and cerebellum region of MM1 subtype and in frontal cor-
tex of VV2 subtype (Fig. 2a, d). This increased phosphory-
lation of cofilin-1 suggests that there is an inactivation of
cofilin-1 in diseased brain. As cofilin is phosphorylated by
LIM-kinase (LIMK) family of protein kinases including
LIMK1 and LIMK2 (which inhibit activity of cofilin by
phosphorylation) [48]; LIMKs are activated through phos-
phorylation at Thr505 and Thr508. We measured a signifi-
cant decrease in total LIMK1 protein levels in cerebellum
and frontal cortex of MM1 subtype vs. control and also in
cerebellum of VV2 subtype (Fig. 2b, e). In contrast, the
level of phosphorylated LIMK1 was significantly upregu-
lated in the frontal cortex MM1 subtype and in cerebellum
VV2 subtype as compared to age-matched control (Fig. 2a,
f). As LIMK1 is regulated upstream by Rock2 and APP, we
further demonstrated alterations in Rock2 and APP protein
levels in frontal cortex and in cerebellum of MM1 and VV2
subtype (Fig. 5).
Time course study in sCJDMM1-inoculated Tg340 mice
showed significant decrease in levels of cofilin-1 protein at
pre-symptomatic and symptomatic stage of the disease
(from 120 to 210 dpi) in cortex region of Met129 mice. In
contrast, cofilin-1 levels were significantly increased in the
cerebellum region at pre-symptomatic and symptomatic
stage of the disease (from 120 to 210 dpi) (Fig. 3a, b). The
p-cofilin(Ser3) levels showed upregulation in the cortex re-
gion ofMM1-M129 mice as compared to VV2-Val129 mice
(Fig. 3a, c–e). The cerebellum region of MM1-Met129 sub-
type sCJD showed a significant decrease of p-cofilin(Ser3)
at pre-symptomatic stage (120 dpi) and upregulation at
symptomatic stage (210 dpi) (Fig. 3d, f). In parallel, the
cerebellum VV2-Val129 subtype showed increase of p-
cofilin(Ser3) only at pre-symptomatic stages (120 dpi)
(Fig. 3a, f).
This early stage regulated response of phosphorylation (de-
activation) of cofilin indicating that cofilin activity decreases
at the pre-symptomatic stage of the disease, and to explore the
mechanism of this altered activity of cofilin-1, we analyzed
changes in LIMK1, the modulator of cofilin phosphorylation.
The MM1-Met129 mice showed significant decrease of
LIMK1 at pre-symptomatic stage of the disease (from 120 to
160 dpi) in cortex region of MM1-Met129 mice cortex
(Fig. 4a, b); however, P-LIMK1 showed significant increase
at pre-symptomatic stage of the disease (120 dpi) in cortex
region ofMM1-Met129mice (Fig. 4d, e). MM1-Met129mice
cerebellum showed upregulation of LIMK1 at pre-
symptomatic stage of the disease (120 dpi) (Fig. 4a, c), and
P-LIMK1 showed significant decrease at pre-symptomatic
stage of the disease (120 dpi) (Fig. 4d, f). VV2-Val129 mice
cerebellum showed upregulation of LIMK1 and P-LIMK1 at
pre-symptomatic stage of the disease (160 dpi) (Fig. 4a, c, f).
Fig. 7 SSH1 and calcineurin in sCJDMM1 and VV2 subtypes. Western
blotting analysis: a SSH1 and calcineurin in four representative cases
each for control, sCJD MM1, and sCJD VV2 cases; GAPDH
immunostaining was used to normalize total protein loading. b, c
Densitometry analysis from four independent (±SD) immunoblotting
experiments of 15 control (Con), 15 MM1, and 15 VV2 cases. The
significance was calculated with one-way ANOVA Friedman test
(*P < 0.05). Region-dependent significantly altered expression is found
in both sCJD subtypes compared to controls. AU arbitrary units
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Fig. 8 Expression of SSH1 and calcineurin at pre-symptomatic and
symptomatic stage of sCJD MM1 and VV2 in mice. Tg340 mice
expressing about 4-fold level of human PrPM129 were infected with
sCJD MM1 and also VV2 10% brain homogenates. Samples were
collected at indicated days post-infection (dpi): pre-symptomatic stage
(60 dpi in VV2, 120 dpi in MM1) and symptomatic stages (120–
183 dpi in VV2 and 160–210 dpi). a SSH1 and calcineurin expression
in the cortex and cerebellum were observed by Western blot analysis
using SSH1 and calcineurin antibodies. b–e Densitometry analysis from
four independent (±SD) immunoblotting experiments of SSH1 and
calcineurin from control and sCJD MM1- and VV2-infected PrPM129
mice in cortex and cerebellum. The significance was calculated with one-
way ANOVA Friedman test (*P < 0.05, **P < 0.01, ***P < 0.001)
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Lastly, to demonstrate the kinases that regulate phos-
phorylation of LIMK, we found significant upregulation
of Rock2 and APP at pre-symptomatic stage of the disease
in MM1-Met129 and VV2-Val129 Tg340 mice (Figs. 5 and
6).
SSH1 and Calcineurin Altered Expression in sCJD MM1
and VV2 Subtypes and in Pre-symptomatic
and Symptomatic Stages of sCJD MM1 Mice
Further, to better understand the aberrant cofilin-1 expression/
activity, we analyzed changes in cofilin phosphatase SSH1
and its upstream regulator calcineurin byWestern blot in fron-
tal cortex and cerebellum samples from sCJD cases with the
subtypes MM1 and VV2, as well as age-matched controls.
Total homogenates of the frontal cortex and cerebellum were
analyzed using SSH1 and calcineurin monoclonal antibodies
(Fig. 7a). Remarkably, in the cerebellum, SSH1 expression
was significantly decreased in both subtypes MM1 and VV2
as compared to age-matched control samples (Fig. 7a, b) while
SSH1 levels were increased in frontal cortex ofMM1 subtype.
However, calcineurin expression was significantly decreased
only in VV2 subtype in the cerebellum (Fig. 7a, c) showing
that the response was region-specific and codon 129 polymor-
phism-specific. Furthermore, sCJD MM1-inoculated mice
demonstrated a significant increase in the expression of
SSH1 at the pre-symptomatic stage (120 dpi), in contrary to
sCJD VV2-inoculated mice showing significant decrease at
pre-symptomatic stage (60 and 120 dpi) in the cortex
(Fig. 8a, b). However, sCJD MM1-inoculated mice demon-
strated a significant decrease in the expression of SSH1 at the
symptomatic stage (183 dpi) in the cortex. The terminal or
death stage showed no significant regulation in both subtypes
of sCJD MM1- and VV2-inoculated mice (Fig. 8a, b). The
cerebellum region of both subtypes of sCJD-inoculated mice
showed differential regulation of SSH1 (Fig. 8a, c). The ex-
pression of calcineurin showed significant decrease in the cor-
tex of sCJD MM1 mice at pre-symptomatic and symptomatic
stages (from 120 to 210 dpi terminal stage). In contrast, in the
sCJD VV2-inoculated mice, the calcineurin expression was
significantly downregulated only in symptomatic stages (from
160 to 183 dpi terminal stage) (Fig. 8a, d). In cerebellum,
calcineurin expression in sCJD MM1-inoculated mice
showed a significant increased expression in the pre-
symptomatic stage and symptomatic terminal stages (120
and 210 dpi terminal stage) (Fig. 8a, e). The sCJD VV2-
inoculated mice in the cerebellum showed a significant upreg-
ulation of calcineurin in the pre-symptomatic stages (60 and
120 dpi) (Fig. 8a, e). However, symptomatic and terminal
death stages showed downregulation (160 and 183 dpi)
(Fig. 8a, e).
siRNA-Induced Gene Silencing of Cofilin-1 Leads
to Dense Accumulation of F-Actin, Activation
of Microglia, and Decreased Cell Viability
To check the cofilin-1-dependent actin depolymerization ac-
tivity, we demonstrated that cofilin-1 siRNA knockdown lead
to increased expression level of F-actin and decreased expres-
sion level of PrPC. Approximately 70–80% of cofilin-1 ex-
pression depletion was achieved in PCNs (Fig. 9a, c). The
immunofluorescence results demonstrated that cofilin-1
siRNA deficit cells showed increased expression level and
dense accumulation of F-actin (Fig. 9a, b). However, PrPC
showed decreased expression and altered localization pattern
(Fig. 9a, d). The percent colocalization of cofilin-1 and F-actin
showed significant decrease in the cofilin-1 depleted PCNs.
However, F-actin and PrPC showed significant upregulation
of percent colocalization in the cofilin-1 depleted PCNs
(Fig. 9e, f).
As cofilin-1 gene deletion leads to lethality in mouse
[49], further, we investigated the effect of cofilin-1 de-
pletion on cell viability in both PrPC wild-type and
knockout PCN cells. Cofilin-1 depletion resulted in de-
creased Cell viability in both PrPC wild-type and knock-
out PCN cells (Fig. 10a) while concomitantly increased
caspase-3 activity (Fig. 10b). Interestingly, PrPC-ex-
pressing PCNs with siRNA cofilin-1 depletion, showed
more viability and less caspase-3 activation as compared
to PrP−/− PCNs depleted with cofilin-1 (Fig. 10a, b);
suggesting protective role of PrPC on cell viability.
As both in vitro and in vivo studies have shown that neu-
ronal apoptosis and neuronal death precedes microglia activa-
tion [50], so accordingly, we investigated the activation status
of microglia in cofilin-1 depleted PCN cultures (PrPC wild-
type and PrPC knockout cells). Here, we demonstrated a cor-
relation between presence and absence of PrPC, and the
cofilin-1 depletion induced microglial activation in primary
cortical neurons (Fig. 10c–e). Immunofluorescence data dem-
onstrated the different populations of microglia after siRNA
against cofilin-1 treatment in PCNs (Fig. 10c) with a shift
towards activated microglia in cofilin-1 depleted cells. These
microglia populations showed marked differences in the ex-
pression of cofilin-1 and p-cofilin with the upregulation of p-
cofilin in activated microglia (Fig. 11a). The colocalization
analysis of cofilin-1, and p-cofilin(Ser3) with Iba1 showed
significant increase shift between p-cofilin and Iba1 in the
cofilin-1-depleted PCNs as compared to control (Fig. 11b,
c). Overall, coflin-1 regional density, distribution, and/or ac-
tivity of microglia and microglia-derived factors may influ-
ence the region-specific role for this cell type (Fig. 13).
Further, it is already been reported that the microglia
showed upregulation in sCJD cases, with increased expression
levels in the frontal cortex in MM1 and in the cerebellum in
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VV2 cases. In the CJDMM1mice, the microglial marker Iba1
also showed upregulation at mRNA level [51]. Our data also
showed region-specific upregulation of iba1 levels, microglia
marker, in sCJD cases for both subtypes MM1 and VV2
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(Fig. 12). We also found significant upregulation of iba1 ex-
pression at pre-symptomatic stage and symptomatic stage of
the disease in MM1-Met129 and VV2-Val129 Tg340 mice
(Fig. 12).
Discussion
Selective Interactive Association Between PrPC
and Cofilin-1
We have previously shown that by using interactomic ap-
proaches, we can isolate cofilin-1 as a binding partner of PrPC
in HpL3–4 cells [46]; however, the prion-specific regulatory re-
sponse of cofilin-1 and its activation during prion disease pro-
gression remained to be determined. In this study, we showed
that the cofilin-1 and phosphorylated form of cofilin at Ser3
interacts and co-sediment with PrPC in primary cortical and cer-
ebellar neurons. Cofilin-1, which is a member of cofilin-actin
cytoskeleton assembly and is involved in abnormal rod forma-
tion [52], specifically in cortical region of AD brain [52], has
shown direct interaction with PrPC in our study, suggesting a role
of cofilin-1 in pathogenesis of Prion diseases. Previously, cofilin-
1 has been shown as an interactive partner of PrPSc [47], further
supporting the notion that there might be some functional asso-
ciation between cofilin-1 and prion protein. Altogether, our re-
sults indicate that there is a functional correlation between PrPC,
PrPSc, and cofilin-1 in relation to strain-specific prion diseases
and with disease progression rate.
Cofilin-Phosphorylation/Dephosphorylation Pathway
in sCJD MM1 and VV2 Subtypes: Early and Terminal
Stage Disease Progression Association
In different cellular processes, actin is modulated by cofilin
[26], and it has been hard to demonstrate that if the cofilin rod
formation has damaging effects on cells, or whether it is the
modification of cofilin pathway at some other step. To
uncover this condition, we have taken an approach to check
the alteration in cofilin-1 upstream pathway at symptomatic
stage (in humans and mice) and pre-symptomatic stage (in
mice) of the disease (Fig. 13).
In our regional and temporal studies, cofilin-1 (de-phos-
phorylated/active form) expression at protein level was signif-
icantly altered in the frontal cortex in the sCJDMM1 subtype.
Interestingly, cofilin-1 (de-phosphorylated/active form) levels
were significantly decreased in the cerebellum in VV2 sub-
type only. Levels of phosphorylated (de-activated) formwhich
is unable to bind to actin were significantly increased in the
frontal cortex in CJD-MM1 and in the cerebellum and frontal
cortex of CJD-VV2 patients, suggesting that there is an in-
crease in the inactivated form (phosphorylated form) of
cofilin-1 in diseased brain. In the case of AD, cofilin
overactivation and rod formation is well known [53, 54]; in
contrast, we observed cofilin inactivation (increased phos-
phorylation) particularly at terminal stage of the disease in
CJD patients, which suggest that response is CJD-specific.
The novelty of our work is to report for the first time changes
in cofilin pathway in CJD, thus indicating an involvement of
cofilin in lesion development in prion diseases.
Time course study in sCJD MM1 and VV2-inoculated
Tg340 mice showed a significant increase of p-cofilin(Ser3)
in the cortex region at pre-symptomatic and symptomatic
stage of the disease (from 120 to 210 dpi). In parallel, the
cerebellum VV2 subtype showed increase of p-cofilin(Ser3)
only at pre-clinical stages (120 dpi). LIMK1; phosphorylation
activator of cofilin-1 at Ser3 showed significant altered regu-
latory response corresponding to the cofilin phosphorylation
state in cortex and cerebellum and in both MM1 and VV2
subtype-inoculated Tg340 mice.
This early stage regulated response of phosphorylation (de-
activation) of cofilin-1 indicates that cofilin-1 activity decreases
at the pre-symptomatic stage of the disease. LIMK1 is responsi-
ble for the phosphorylation of cofilin and is activated by phos-
phorylation at thr505 and th508, which showed a 2-fold increase
in the phosphorylation level of kinase, which indicates a stronger
LIMK activity as early disease response. Finally, among the
kinases that phosphorylate LIMK is RhoA-associated kinase
(Rock2) whose activity is regulated by small G protein RhoA
[27–29] and amyloid precursor protein (APP). Initially, there was
an increase in Rock2 levels at 60 dpi, which return to normal at
120 dpi, and then increase again at 180 dpi, probably associated
with different pattern of PrPSc aggregates in these mice. We
previously reported that the RhoA activity was regulated by
phosphorylation of myosin light-chain (MLC) in association
with Arf1-dependent PI3K pathway [36]. The APP showed sig-
nificant upregulation at pre-symptomatic stage of the disease in
MM1- and VV2-inoculated Tg340 mice. These data argue that
the phosphorylation (de-activation) of cofilin at Ser3 is regulated
by the upstream activation of the RhoA-Rock2-LIMK1-pathway
at early stage of the disease.
Fig. 9 Colocalization of F-actin, cofilin-1, and PrPC in PCNs after
depletion of cofilin-1. Primary cultures of mouse cortex neurons
(PCNs) were prepared from pregnant mice at embryonic day 14; the mice
were prnp (the PrP-encoding gene). PCNs were treated with cofilin-1
siRNA and fixed and immunostained for F-actin, cofilin-1, and PrPC
examples from a single neuron showing a co-immunostaining of F-
actin and cofilin-1, F-actin, and PrPC. b, c, d Quantification of images
taken in different regions of neurons fixed after siRNA depletion and
showed a significant (**P < 0.01) increase in F-actin expression and a
decrease of cofilin-1 expression (***P < 0.001) and PrPC (***P < 0.001).
e, f Pearson’s colocalization correlation coefficient rp (−1 ≤ rp ≤ 1) ex-
periments and graph was generated by ImageJ (WCIF plugin) software.
Quantification of colocalization was determined with and without cofilin-
1 siRNA treatment by ImageJ (WCIF plugin) software. Densitometry
analysis from four independent (±SD) experiments and significance was
calculated with Student’s t test (**P < 0.01, ***P < 0.001)
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The reactivation of cofilin-1 by dephosphorylation at Ser3
is SSH1 dependent in neurons [55]. However, pathways for
p21-LIM kinase activation, protein kinase C/G, or reactive
oxygen species were not responsible for these alterations
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[56]. Although other kinases and phosphatases can affect
cofilin-1 activity, LIMK1 and SSH1 show the highest sub-
strate specificity [26]. Remarkably, phosphorylation at serines
937 and 978 inactivates SSH1 [30]. Further, not only cofilin-1
but also LIMK1 is dephosphorylated by SSH1 activity. So,
SSH1 can control cofilin-1 activity either directly or indirectly
through an upstream regulation of LIMK1 [30].
To further explore the possible mechanism responsible for
altered expression/activity of cofilin-1, wemeasured changes in
cofilin phosphatase SSH1 and its upstream regulator calcine-
urin and found the altered response at early disease pre-
symptomatic stage in both subtypes. Calcineurin is responsible
for cofilin dephosphorylation either directly or indirectly via an
intermediary phosphatase SSH1. Calcineurin has been impli-
cated in the regulation of synaptic plasticity and memory [57,
58]. Hyperactivation of calcineurin leads to synaptic abnormal-
ities and neuronal death [59]. On the other side, SSH1 also
deactivates LIMK1 to regulate cofilin activation state and could
be the risk factor for the modulation of the whole pathway. The
mechanism responsible for cofilin-1 activation or inactivation/
Fig. 10 PCN viability and activation of microglia after depletion of
cofilin-1. Primary cultures of mouse cortex neurons (PCNs) were
prepared from pregnant mice at embryonic day 14; the mice were prnp
(the PrP-encoding gene). PCNs were treated with cofilin-1 siRNA. a Cell
viability wasmeasured byMTS assay 48 h post transfection. The viability
values are shown as absorbance at 490 nm. Data points are the
means ± SEM of values from four different experiments. The cells
expressing PrPC displayed elevated level of cell viability under cofilin-1
depletion as compared with out PrPC. The significance was performed by
one-way ANOVAFriedman test (**P < 0.01, ***P < 0.001). bCaspase-3
activity was detected by fluorescence measurement of the cleaved pNA
from the substrate peptide DEVD-pNA. Data points are the means ± SD
of values from four different experiments. The cells expressing PrPC
displayed decreased level of caspase-3 cleavage activity under cofilin-1
depletion as compared with out PrPC. The significance was performed by
one-way ANOVA Friedman test (**P < 0.01, ***P < 0.001). c
Colocalization of PrPC, Iba1, and p-cofilin(Ser3) in PCNs after depletion
of cofilin-1, fixed and immunostained. d, e Quantification of images
taken in different regions of neurons and showed a significant altered
expression of activated and inactivated Iba1-positive microglia after
siRNA depletion in the presence and absence of PrPC expression.
Quantification of colocalization was determined by ImageJ (WCIF
plugin) software, and significance was calculated with Student’s t test
(**P < 0.01, ***P < 0.001)
Fig. 11 Colocalization of cofilin-1 and p-cofilin(Ser3) in PCNs after
depletion of cofilin-1. Primary cultures of mouse cortex neurons
(PCNs) were prepared from pregnant mice at embryonic day 14; the mice
were prnp (the PrP-encoding gene). PCNs were treated with cofilin-1
siRNA and fixed and a co-immunostained for cofilin-1 and p-
cofilin(Ser3). b, c Quantification of images taken in different regions of
neurons fixed after siRNA depletion and showed a significant
redistribution of p-cofilin(Ser3) in activated form of Iba1-positive
microglia. Pearson’s colocalization correlation coefficient rp
(−1 ≤ rp ≤ 1) experiments and graph were generated by ImageJ (WCIF
plugin) software. Quantification of colocalization that was determined
with and without cofilin-1 siRNA treatment showed significant increase
of p-cofilin(Ser3) in Iba1-positive microglia. Densitometry analysis from
four independent (±SD) and significance was calculated with Student’s t
test (***P < 0.001)
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phosphorylation may be different in both subtypes and brain
regions and dependent, at least in part, on PrPSc aggregates.
Dense Accumulation of F-Actin and Activation
of Microglia
The activation of cofilin-1 (dephosphorylation) is a key factor
for the dynamics in actin depolymerization and cytoskeleton
assembly [60]. Cofilin phosphorylation was aberrantly upregu-
lated in the terminal stage of the disease, in parallel to the
reduction of the SSH1. Interestingly, our findings indicate that
cofilin-1 depletion leads to denser actin filaments corresponding
to repression of level of PrPC in PCNs. The reason for decreased
levels of PrPC might be altered actin dynamics leading to pro-
teasome degradation of PrPC instead of its transportation to the
cell membrane due to lack of cofilin-1-dependent remodeling of
actin cytoskeleton [61] as the localization pattern of PrPC was
also altered in cofilin-1 depleted cells. Several recent studies also
support the idea that alterations in cofilin activation state con-
tribute to actin pathology in neurodegeneration.
Fig. 12 Iba1 expression in sCJD MM1 and VV2 subjects and at pre-
symptomatic and symptomatic stage of sCJD MM1 and VV2 mice.
Western blotting analysis: a Iba1 protein expression in four
representative cases each for control, sCJD MM1, and sCJD VV2 cases
and in Tg340 mice infected with sCJD MM1 and also VV2 10% brain
homogenates. Samples were collected at indicated days post-infection
(dpi): pre-symptomatic stage (60 dpi in VV2 120 dpi in MM1) and
symptomatic stages (120–183 dpi in VV2 and 160–210 dpi). b
Densitometry analysis from four independent (±SD) immunoblotting
experiments of 15 control (Con), 15 MM1, and 15 VV2 cases. c, d
Densitometry analysis from four independent (±SD) immunoblotting
experiments Iba1 from control and sCJD MM1- and VV2-infected
PrPM129 mice in cortex and cerebellum. The significance was
calculated with one-way ANOVA Friedman test (*P < 0.05). Region-
dependent significantly altered expression is found in both sCJD
subtypes compared to controls. AU arbitrary units
Fig. 13 Schematic representation




stage and symptomatic stage of
the disease. Yellow highlighted
area presents alterations
demonstrated in this study (color
figure online)
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The activation of microglial is a trademark of the
neuroimmunological response in prion disease [62]. Recent re-
port demonstrated the suggestive role of microglia during the
clearance of cofilin aggregation [53]. Our data demonstrated
different populations of microglia in response to depletion of
cofilin-1 and presence of PrPC. The different activation statuses
of microglia after depletion of cofilin-1 demonstrate a link be-
tween cofilin-1, PrPC, andmicroglia activation during the course
of prion disease. These different microglia populations showed
marked differences in the expression of dephosphorylated form
(active form) in non-active microglia and phosphorylated form
(inactivated) of cofilin in activated form of microglia.
However, the upregulated microglia expression showed
disease subtype and brain region-specific response in CJD
patients (Fig. 12). CJD-MM1 patients showed significantly
and specifically upregulated microglia in frontal cortex; how-
ever, CJD-VV2 subtype patients showed this response specif-
ically in cerebellum [51].
Altogether, our data demonstrated the different populations
of microglia in response to depletion of cofilin-1, presence of
PrPC, and disease subtype manner. These microglia popula-
tions showed marked differences in the expression of dephos-
phorylated form of cofilin in non-active microglia and phos-
phorylated form of cofilin in activated microglia. Cofilin-1
regional density, distribution, and/or activity of microglia
and microglia-derived factors may influence the region-
specific role for this cell type.
This regional and subtype-specific post-translational al-
tered pattern of cofilin-LIMK-APP pathway in sCJD MM1
and VV2 and a modified temporal response in sCJD MM1
and VV2 mice could correlate with the disease severity and
progression in neurons in correlation with microglia. The
demonstration in respect with subtype manner could prove
to be the cardinal specific targets for therapeutic intervention.
Conclusion
In conclusion, this study demonstrates altered cofilin-LIMK-
SSH1 pathway in sporadic CJD-MM1 and VV2 subtypes at
early disease stage in a strain-specific subtype manner. The
regulated response may contribute actin cytoskeleton abnor-
malities that ultimately lead to synapse and dendritic spine
loss, as actin dynamics are responsible for synapse formation,
maturation, and stability and for maintenance of dendritic
spines in CJD. Taken together, our findings highlight a key
pre-and early symptomatic role of cofilin-1 activation in neu-
rodegeneration specifically as an early regulatory response,
suggesting the idea that targeting the cofilin signaling axis
might be a promising strategy and a potential early diagnostic
approach useful to reveal therapeutic strategy for misfolded
protein differential response.
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